Respiratory syncytial virus (RSV) is estimated to cause 177,000 hospitalizations and 14,000 deaths in adults 65 and older in the US every year, and yet it goes largely unrecognized. With new RSV-specific antivirals and vaccines in the research pipeline, we need to begin raising awareness of the burden of RSV among older adults…
There’s a disease that kills up to 18,000 US adults age 65 years and older each year. It can cause pneumonia, bloodstream infections (sepsis), meningitis, and ear and sinus infections. As many as 900,000 US adults contract it each year — 400,000 of whom require hospitalization. Pneumococcal disease is a serious concern for anyone over the age of 65, but there are safe and effective vaccines to help prevent it.
Vaccines are among the most cost-effective clinical preventive services yet adult vaccination rates remain well below public health goals, despite the impact of vaccine-preventable diseases in the US. The recently released National Adult Immunization Plan (NAIP) provides an overview of recommended actions to be undertaken by federal and non-federal partners to protect public health and achieve optimal prevention of infectious diseases through vaccination, specifically vaccination of adults.
Immunization is one of the 10 great public health successes of the 20th century. Through the use of vaccines, measles and rubella have been eliminated in the western hemisphere, polio has been eliminated from most of the world, and smallpox has been completely eradicated. However, while childhood vaccination rates are relatively high in the US, adult vaccination rates remain low.